Page last updated: 2024-09-05

sb 203580 and cardiovascular agents

sb 203580 has been researched along with cardiovascular agents in 2 studies

Compound Research Comparison

Studies (sb 203580)	Trials (sb 203580)	Recent Studies (post-2010) (sb 203580)	Studies (cardiovascular agents)	Trials (cardiovascular agents)	Recent Studies (post-2010) (cardiovascular agents)
3,489	4	1,137	17,645	1,480	6,891

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (50.00)	29.6817
2010's	1 (50.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Asakura, M; Asanuma, H; Fukushima, T; Hori, M; Kitakaze, M; Kuzuya, T; Liao, Y; Mori, H; Node, K; Ogai, A; Ogita, H; Papst, PJ; Sakata, Y; Sanada, S; Shinozaki, Y; Takashima, S; Terada, N; Yamada, J	1
Armstead, WM; Cines, DB; Higazi, AA; Kiessling, JW; Riley, J	1

Other Studies

2 other study(ies) available for sb 203580 and cardiovascular agents

Article	Year
Cardioprotective effect afforded by transient exposure to phosphodiesterase III inhibitors: the role of protein kinase A and p38 mitogen-activated protein kinase. Circulation, 2001, Aug-07, Volume: 104, Issue:6 Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Animals; Blood Flow Velocity; Bucladesine; Calcium-Calmodulin-Dependent Protein Kinases; Cardiovascular Agents; Cyclic AMP-Dependent Protein Kinases; Cyclic Nucleotide Phosphodiesterases, Type 3; Dogs; Enzyme Inhibitors; Flavonoids; Hemodynamics; Imidazoles; Indoles; Isoquinolines; Maleimides; Milrinone; Mitogen-Activated Protein Kinases; Myocardial Infarction; p38 Mitogen-Activated Protein Kinases; Phosphodiesterase Inhibitors; Protein Kinase C; Pyridines; Pyridones; Sulfonamides; Ventricular Fibrillation	2001
PAI-1-derived peptide EEIIMD prevents impairment of cerebrovasodilation by augmenting p38 MAPK upregulation after cerebral hypoxia/ischemia. American journal of physiology. Heart and circulatory physiology, 2010, Volume: 299, Issue:1 Topics: Animals; Animals, Newborn; Anthracenes; Blood Pressure; Carbon Dioxide; Cardiovascular Agents; Cerebrovascular Circulation; Disease Models, Animal; Dose-Response Relationship, Drug; Enzyme Activation; Female; Hypercapnia; Hypotension; Hypoxia-Ischemia, Brain; Imidazoles; Injections, Intravenous; Isoproterenol; JNK Mitogen-Activated Protein Kinases; Male; Oligopeptides; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Pia Mater; Protein Kinase Inhibitors; Pyridines; Swine; Time Factors; Up-Regulation; Vasodilation; Vasodilator Agents	2010

Article

Year

Cardioprotective effect afforded by transient exposure to phosphodiesterase III inhibitors: the role of protein kinase A and p38 mitogen-activated protein kinase.

Circulation, 2001, Aug-07, Volume: 104, Issue:6

Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Animals; Blood Flow Velocity; Bucladesine; Calcium-Calmodulin-Dependent Protein Kinases; Cardiovascular Agents; Cyclic AMP-Dependent Protein Kinases; Cyclic Nucleotide Phosphodiesterases, Type 3; Dogs; Enzyme Inhibitors; Flavonoids; Hemodynamics; Imidazoles; Indoles; Isoquinolines; Maleimides; Milrinone; Mitogen-Activated Protein Kinases; Myocardial Infarction; p38 Mitogen-Activated Protein Kinases; Phosphodiesterase Inhibitors; Protein Kinase C; Pyridines; Pyridones; Sulfonamides; Ventricular Fibrillation

2001

PAI-1-derived peptide EEIIMD prevents impairment of cerebrovasodilation by augmenting p38 MAPK upregulation after cerebral hypoxia/ischemia.

American journal of physiology. Heart and circulatory physiology, 2010, Volume: 299, Issue:1

Topics: Animals; Animals, Newborn; Anthracenes; Blood Pressure; Carbon Dioxide; Cardiovascular Agents; Cerebrovascular Circulation; Disease Models, Animal; Dose-Response Relationship, Drug; Enzyme Activation; Female; Hypercapnia; Hypotension; Hypoxia-Ischemia, Brain; Imidazoles; Injections, Intravenous; Isoproterenol; JNK Mitogen-Activated Protein Kinases; Male; Oligopeptides; p38 Mitogen-Activated Protein Kinases; Phosphorylation; Pia Mater; Protein Kinase Inhibitors; Pyridines; Swine; Time Factors; Up-Regulation; Vasodilation; Vasodilator Agents

2010